Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04675294
Title Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.

head and neck squamous cell carcinoma


Evorpacept + Pembrolizumab


Age Groups: senior | adult
Covered Countries USA | ESP | CAN | BEL

No variant requirements are available.